Christine Borowski - 12 Dec 2024 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Reporting relationship: Director
Issuer ticker: VYNE
Reported as of: 12 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Dec 2024, 16:15:33 UTC
Prior SEC filing: 03 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Mutya Harsch, Attorney-in-Fact

Key filing fact

Christine Borowski filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 13 Dec 2024.

Key facts

This page summarizes Christine Borowski's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Dec 2024, 16:15.

Change

Previous filing in this sequence was filed on 03 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 12 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $2.40
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date.